Overall survival (OS) among patients who experienced an immune-related adverse event (irAE). A statistically significant OS difference was noted amongst those experiencing any irAE versus those who did not (p=<0.001), with greater OS benefit in patients reporting 3 or more events (p=<0.001).

Twelve-week landmark survival analysis of individual irAEs in the combined patient population (n=143). Rash and vitiligo were also associated with statistically significant OS differences (p=0.001 and p=0.012, respectively).